Tom Eisiminger, Jr.

President & Chief Executive Officer

Tom Eisiminger is the President, Chief Executive Officer, and a member of the Board of Directors at Regenesis. He joined the company in 2006 following a brief tenure at GlaxoSmithKline, and has since held a series of progressive leadership roles culminating in his current position.

A decorated combat veteran, Tom served over 20 years in the U.S. Army, holding command positions from platoon to battalion level. He led the Army’s largest geographically dispersed Recruiting Battalion, overseeing operations across Southwest Washington, Oregon, Northern California, Hawaii, Korea, Japan, Guam, American Samoa, the Commonwealth of the Northern Mariana Islands, and the Freely Associated States including the Republic of the Marshall Islands, Republic of Palau, and the Federated States of Micronesia. Under his leadership, his unit twice earned recognition as the top recruiting battalion in the Army.

Tom is a passionate advocate for veterans. He serves as President of the Veterans Medical Leadership Council (VMLC), a Phoenix-based nonprofit dedicated to ensuring quality medical and mental health care for veterans and promoting initiatives that honor their service to the city, state, and nation. He is a member of the Veterans of Foreign Wars, the American Legion, and the Disabled American Veterans, and has served on the boards of several veteran-focused nonprofits. In recognition of his service and advocacy, Tom was inducted into the Arizona Veterans Hall of Fame in 2018.

In addition to his work with veterans, Tom serves on the Board of Directors of the American Diabetes Association (ADA) for the Arizona, New Mexico, and Utah region.

Tom holds a B.S. from the U.S. Military Academy at West Point, an M.A. in National Security and Strategic Studies from the Naval War College, and an MBA from Marylhurst University in Portland, Oregon.

Lou Burts

Senior Vice President, Sales

Mr. Burts brings 20 years of healthcare sales leadership experience to Regenesis, with a focus on medical devices, revenue cycle management, capital equipment, and contracting. He has held leadership roles as a sales representative and regional manager with Boston Scientific in implantable cardiac devices, served as a business development director for a SaaS-based RCM product, a regional manager at Henry Schein, and a regional director for Integra Surgical Reconstruction. He is passionate about building high-performing teams and fostering a culture of collaboration and accountability. At Regenesis, he focuses on driving growth while enhancing customer and patient experiences through innovative medical solutions. An Army Veteran (Infantry), Mr. Burts holds a BS in Ergonomic Engineering from the United States Military Academy, an MS in Leadership/Organizational Change from Troy University, and an MBA from Texas A&M. Currently, he is pursuing a doctoral degree in business administration at Texas State University.

Scott Steinman

Vice President and Chief Financial Officer

Mr. Steinman joins Regenesis with over 30 years of experience encompassing all aspects of business management and accountability while anchored in the Finance chair.  Scaling organizations, improving employee engagement, and building financial acumen in privately held, VC, PE sponsored, and publicly traded multinational entities have been staples of Scott’s career.  Responsibility for leading multiple tuck-in and stand-alone acquisitions, tactical divestitures, and successful exits have added to significant organic and strategic value creation realized by all stakeholders involved.  With over 15 years’ experience of market leading growth in MedTech and Life Science markets, Scott is honored to be supporting the Regenesis team, the clinicians, and ultimately the recipients of Regenesis’ energy-based medical products and services.  Naturally inquisitive and a career student at heart, Scott holds active CPA licenses in Canada and the U.S.A., has honed his service and performance outcome acumen through Executive Leadership studies at Harvard Business School, and received his MBA from Queen’s University School of Business in Kingston, Ontario.

Randy Chavez

Vice President, Regulatory Affairs and Quality Assurance

Mr. Chavez is a seasoned regulatory affairs and quality executive with nearly twenty years of expertise in medical device market access, FDA clearances, and quality system compliance. He brings a patient-centered approach focusing on balancing safety with business goals, leveraging regulatory complexity as a competitive advantage. Career highlights include pioneering innovative regulatory pathways, securing first-to-market clearances, and maintaining exemplary FDA inspection records.

He is recognized for driving creative, compliant solutions to advance products while upholding the highest standards of quality and patient care. As Vice President at Regenesis Biomedical his responsibilities span regulatory strategy, FDA submissions, and FDA/ISO/IEC compliance and is known for data-driven decision-making and cross-functional influence, that aligns regulatory strategy with business growth and cultivates high-performing teams built on trust and accountability.

Mr. Chavez has strong ties to Arizona State University, earning a B.S. in Chemical Engineering, an M.S. in Regulatory Science, and giving back to Arizona State University, volunteering for the Clinical Research Management Advisory Board and serving as a mentor for students with an interest in entering the Regulatory field.

Kevin Kuttin

Executive Director of Information Technology

Mr. Kuttin leads Regenesis’ IT strategy and infrastructure to support growth and innovation. With over 18 years of experience in IT leadership across healthcare, logistics, and biopharmaceuticals, he has driven successful digital transformations, including a transition to a Cloud-First architecture and the implementation of modern ERP and eQMS systems. His expertise in cloud infrastructure, data management, and compliance has been instrumental in optimizing operational efficiency and supporting Regenesis’ business objectives. 

Prior to joining Regenesis, he held key leadership roles at The RealReal, Echo Global Logistics, and InnerWorkings, where he managed IT operations, led large international teams, and introduced innovative solutions that improved service delivery and saved millions in operational costs. A recognized leader in the IT space, he is a dedicated mentor and advocate for team development, fostering a culture of collaboration, continuous growth, and innovation. He combines strategic vision with hands-on expertise to enhance both technology and business outcomes, driving initiatives that strengthen Regenesis’ capabilities and support its mission to deliver advanced medical solutions. 

Outside of work, he enjoys sports, snowboarding, and playing piano, which provide balance and fresh perspectives that inform his leadership approach. 

Jenna Bonitz

Director of Engineering

Jenna Bonitz brings extensive engineering leadership experience to Regenesis, with a focus on high-performance circuitry materials and medical devices. She has held advancing leadership roles throughout her career in both R&D and operations settings, most recently serving as Program Manager and Product Engineering Manager for implantable cardiac monitors at Medtronic, and Director of Engineering at Regenesis. Her background spans highly regulated industries—including medical device, automotive, and OSHA’s Process Safety Management—which strengthens her effectiveness as a quality leader, ensuring compliance, consistency, and a strong culture of continuous improvement.

At Regenesis, Jenna focuses on advancing the product pipeline and building scalable quality infrastructure to deliver best-in-class products to patients as efficiently as possible. Her leadership emphasizes accountability, collaboration, and creating momentum to drive meaningful business outcomes. She holds a Bachelor of Science in Chemical Engineering from Northeastern University and is a certified Project Management Professional (PMP).

Kay Bredvik

Director of Human Resources

Ms. Bredvik serves as Executive Director of Human Resources at Regenesis, bringing over eight years of HR leadership and more than a decade of healthcare operations experience. She began her career as an executive assistant in healthcare, supporting provider relations and physician recruiting, before transitioning into HR in the automotive services industry. There, she built and led HR departments supporting rapid growth from 95 to over 400 employees, overseeing hiring, process development, and organizational operations. 

She played a key role in acquisitions, managing HR integration across multiple locations from the Midwest to California. She has extensive experience driving cultural and organizational change, establishing team-focused environments, and ensuring the right talent is recruited to support company growth. At Regenesis, she is dedicated to cultivating a collaborative, mission-driven team culture that aligns with the company’s commitment to veterans and high-performing teams. 

Ms. Bredvik holds an undergraduate degree in Healthcare and Finance, a Master’s in Business, and is a certified Senior Professional in Human Resources (SPHR). Outside of work, she enjoys hiking, skiing, and dirt biking, embracing the outdoors and adventurous pursuits. 

Erica Tassone, PhD

Vice President, Research & Development

Dr. Tassone is an expert in molecular biology and genomics, with extensive experience in data analysis, experimental design, and molecular techniques. She earned her Ph.D. in Biology with a focus on Population Genetics from the Department of Life Sciences at Arizona State University. With over 15 years of experience in molecular biology, her work has contributed to more than two dozen publications across a variety of study organisms, including primates, crops, pests, and humans. She has presented her research at national conferences and has led collaborative projects that apply cutting-edge technology and hypothesis-driven experimental design to advance translational research. At Regenesis, Dr. Tassone is dedicated to using her expertise to drive innovation in patient-focused therapies and support the company’s mission of improving outcomes through advanced medical solutions. 

Don Tate

Vice President, Operations

Richard D. Shirk – Chairman

Chairman

Mr. Shirk has been a Director of Regenesis since April 2012. Richard D. Shirk has more than 30 years of experience in insurance, employee benefits, and healthcare, and over 20 years of experience in investment management. Mr. Shirk was President, CEO and Chairman of Cerulean Companies, the holding company of Blue Cross Blue Shield of Georgia, and was President and CEO of Blue Cross Blue Shield of Georgia from 1992 to 2001. Mr. Shirk also held senior officer positions with The Equitable Life Assurance Society, Equicor, and Cigna. He has served on the Board and as Lead Director of Amerigroup, as well as several privately held companies. He currently serves on the SSGA/SSIIT and Elfun mutual funds. His community service includes the Boards of the Metro Atlanta YMCA, the Woodruff Arts Center and its investment committee, and the Healthcare Georgia Foundation and its investment committee. He has served on the Board of the Southeastern Region American Red Cross Blood Services and as Chair of the American Red Cross Metro Atlanta Chapter Board. He is a Trustee Emeritus and graduate of Gettysburg College.

Jack Ahrens II

Mr. Ahrens is a founding General Partner of TGap Venture Capital Funds, headquartered in Kalamazoo, Michigan. TGap I is a $20 million early stage, Midwest focused venture capital fund established in August of 2002 and TGap II is a $26 million fund established in 2008. Jack has been a venture capitalist and fund administrator since 1979; first as President of United Capital Corporation of Illinois (an SBIC), since 1983 as a General Partner of Pathfinder Venture Capital Funds I,II, III. Prior to that he had seven years of experience in bank trust investments and operations. He became a Chartered Financial Analyst (CFA) in 1982 and has advanced training at the American Institute of Banking, NASBIC Management Institute, and Stanford Advance Management College. He has served on many Boards during his career including Afmedica, Inc., Central Data, Inc., Micro Business Applications, Inc., MedVantx, Inc., MinuteClinic, Inc., NeoChord, Inc., Vector General, Inc. and he is the Chairman of the Great Lakes Entrepreneur Quest. He has been on several 501C3, Not for Profit Boards, and has held various officer roles in these organizations. He is a graduate of Indiana University.

Tom Eisiminger, Jr.

President and Chief Executive Officer

Tom Eisiminger is the President, Chief Executive Officer, and a member of the Board of Directors at Regenesis. He joined the company in 2006 following a brief tenure at GlaxoSmithKline, and has since held a series of progressive leadership roles culminating in his current position.

A decorated combat veteran, Tom served over 20 years in the U.S. Army, holding command positions from platoon to battalion level. He led the Army’s largest geographically dispersed Recruiting Battalion, overseeing operations across Southwest Washington, Oregon, Northern California, Hawaii, Korea, Japan, Guam, American Samoa, the Commonwealth of the Northern Mariana Islands, and the Freely Associated States including the Republic of the Marshall Islands, Republic of Palau, and the Federated States of Micronesia. Under his leadership, his unit twice earned recognition as the top recruiting battalion in the Army.

Tom is a passionate advocate for veterans. He serves as President of the Veterans Medical Leadership Council (VMLC), a Phoenix-based nonprofit dedicated to ensuring quality medical and mental health care for veterans and promoting initiatives that honor their service to the city, state, and nation. He is a member of the Veterans of Foreign Wars, the American Legion, and the Disabled American Veterans, and has served on the boards of several veteran-focused nonprofits. In recognition of his service and advocacy, Tom was inducted into the Arizona Veterans Hall of Fame in 2018.

In addition to his work with veterans, Tom serves on the Board of Directors of the American Diabetes Association (ADA) for the Arizona, New Mexico, and Utah region.

Tom holds a B.S. from the U.S. Military Academy at West Point, an M.A. in National Security and Strategic Studies from the Naval War College, and an MBA from Marylhurst University in Portland, Oregon.

Thomas Greer

Mr. Greer is a founder and Partner of Fulcrum Equity Partners. He has over 20 years of investment, financial and operating experience. Mr. Greer was the founder, President and Chief Executive Officer of Regency Healthcare, Inc. (“Regency”) a provider of hospice services throughout the Southeast. He grew Regency to 5 offices, 120 employees in 3 years which culminated with the sale of a majority of Regency to EDG Partners, an Atlanta based private equity firm, in February 2006. Mr. Greer served as Chairman of the Board at the successor to Regency, Regency Healthcare Group, LLC, up until the sale of Regency to a Chicago based private equity firm in April 2011. In addition, Mr. Greer previously served on the boards of Implantable Provider Group and SunCrest Healthcare, both Fulcrum portfolio companies that had successful exits. Currently he serves on the board of directors/managers of Enduracare Acute Care Services, LLC. Mr. Greer is also on the board of Special Olympics Georgia. Prior to founding Regency he was Vice President of Healthcare Investment Banking for Robinson Humphrey where he worked on mergers, acquisitions, private placements, and public offerings for healthcare and life science companies. Prior to Robinson Humphrey Mr. Greer was a manager in the Corporate Finance and Investment Banking Group at Eli Lilly & Company in Indianapolis, IN. He worked exclusively on structuring and negotiating licensing arrangements, joint ventures, acquisitions and investments with domestic and international biotechnology and pharmaceutical companies. Prior to Eli Lilly, he served as Director in KPMG’s Corporate Finance practice where he executed equity raises, debt placements, sell side and buy side transactions. Additionally, he served as a Director in PriceWaterhouseCoopers Corporate Value Consulting group. Mr. Greer received his B.S. degree in Finance from Clemson University and his Masters of Business Administration degree from Wake Forest University.

R. King Nelson

Mr. Nelson has been a Director of Regenesis since July 2014. King Nelson has over 35 years of diverse experience and expertise with medical devices. He is currently CEO and Director of Q’Apel Medical, a Neurovascular company. He also served as CEO, President, and Director of Uptake Medical; as President and CEO of Kerberos Proximal Solutions, which was acquired by FoxHollow; and as President and CEO of VenPro, which was acquired by Medtronic. Prior to that, he spent 19 years with Baxter and American Hospital Supply Corporation in roles that included division President for Dade Diagnostics, Baxter Perfusion Services, and Bentley Labs. He currently serves on the Board of Directors for of CardieX (ASX: CDX), a lifescience digital company. He graduated from Texas Tech University and has an MBA from the University of Miami Herbert Business School.

Henry Newman

Mr. Newman is a co-founder and General Partner with Solstice Capital, a Boston based venture capital firm, and has over 35 years of venture capital investing, operations and public accounting experience. For more than seven years, Mr. Newman was a Vice President of BancBoston Ventures Inc., a venture capital subsidiary of Bank of Boston. Previously, he held various financial management positions at the Bank of Boston and was a CPA at Coopers & Lybrand. Mr. Newman is a Director of CodeRyte, and was formerly a Director of CellzDirect, Lipton Corporate Childcare and Proton Energy Systems, Inc. He serves on the Investment Advisory Committee of Commons Capital LLC, a positive impact venture fund. Mr. Newman graduated from Bowdoin College and received an MBA from the Wharton School at the University of Pennsylvania.

Marvin Slepian, MD

Marvin J. Slepian, M.D. is a Regents’ Professor at the University of Arizona; with Professorships in Medicine, Medical Imaging, BioMedical Engineering (Associate Dept. Head), Materials Sciences and Engineering, Chemical and Environmental Engineering, as well as being a McGuire Scholar in the Eller College of Management. Dr. Slepian is the founder and Director of ACABI – the Arizona Center for Accelerated Biomedical Innovation – an across the university “creativity engine,” to drive innovation, novel solution development and real-world translation. In parallel with his clinical career Dr. Slepian has had an extensive research career leading to the development of innovative diagnostics and therapeutics for cardiovascular diseases. His work has focused on the development and use of novel biomaterials for tissue engineering, drug delivery and medical device development. His lab has developed many novel diagnostics and therapeutics which have found their way into clinical use today including: drug-eluting stent technologies, stent coatings, “polymer paving,” surgical anti-adhesive barriers, stretchable and biodegradable electronics, “wearables,” synthetic tissue sealants, myocardial revascularization and cell delivery methods and cardiovascular prosthetic devices – including the only FDA approved total artificial heart. He is the author or co-author of more than 250 articles, textbook chapters and abstracts, published in journals such as Science, Nature Materials, PNAS, PlosOne, Circulation, and the New England Journal of Medicine. He also serves on multiple editorial review boards. He is a prolific inventor with more than 100 issued and filed patents and has been the founder of numerous medical device companies including FOCAL (NASDAQ), Endotex, Angiotrax, Hansen Medical (NASDAQ), Arsenal, 480 BioMedical, MC10 and SynCardia, and has been involved in bringing many new devices through the FDA regulatory process into clinical use, including most notably the total artificial heart. He has received multiple awards for his academic and translational research activities including: the American Heart Association award for the most significant advance in cardiovascular medicine, the AZBio Pioneer Award (2017) for Lifetime Achievement in Biomedical Science Innovation, and in 2019 was named daVinci Fellow – the highest recognition of the University of Arizona College of Engineering; and received the Daniel Drake Medal – the highest distinction of the University of Cincinnati College of Medicine for outstanding innovative medical research. In 2020 Dr. Slepian was selected as Founders’ Lecturer – the highest honor of the U Arizona College of Medicine. Dr. Slepian is an elected fellow of the American Institute for Medical and Biological Engineering (AIMBE), a fellow of the National Academy of Inventors (NAI), and is an elected member of BEMA – the Biomaterials Engineering Materials and Applications (BEMA) Roundtable, of the National Research Council of the National Academies. He is the Immediate Past-President of the International Society for Mechanical Circulatory Support (ISMCS) is and was recently elected President of the American Society for Artificial Internal Organs (ASAIO).

Marissa Carter, PhD

Clinical Trial Design

Marissa Carter is President of Strategic Solutions and holds an MA in biochemistry from Oxford University and a PhD in chemistry from Brandeis University. Dr Carter has an extremely broad background in science, and has worked in many medical fields, as well as chemistry, biochemistry, engineering, and materials science. She believes passionately in interdisciplinary research as the key to understanding medical problems, and brings to the table many different disciplines to help solve challenging issues. She is also a veteran businesswoman, and has worked for many large corporations, such as GTE, Chevron, and Solvay, in research, pilot and industrial engineering, marketing and sales, and product development. She is a biostatistician, epidemiologist, EBM practitioner, and a health economist. Dr. Carter spends most of her time designing, monitoring, and analyzing clinical studies as well as assisting manufacturers on medical devices and biologics approvals and works in the fields of wound care, epidemiology, ophthalmology, orthopedics, and quality of life. For many years she has collaborated with the FDA, CMS, payer, and other wound care organization personnel to help approve new clinical trial endpoints, conduct CACs, and advance improve the way we do wound care research. She is the author or coauthor of over 130 peer-reviewed papers and book chapters in medical and chemical research and is a peer reviewer for dozens of different medical journals.

Bryan Fisher, MD

Vascular Surgeon

Dr. Bryan T. Fisher Sr. is a board certified Vascular surgeon and Physician Lead for Vascular Services for the HCA Tristar Division in Middle Tennessee. Uniquely qualified to address the challenges and solutions aimed at the delivery of high quality patient care, Dr. Fisher is consistently recognized by his peers as a caring professional and respected collaborative colleague in the local and international community.

Dr. Fisher graduated with honors from Tennessee State University and became a Ronald McNair and MARC Scholar. He was accepted into the UW Madison School of Medicine and Public Health, but deferred one year to teach elementary school at Belmont Elementary School in Woodbridge, VA. After medical school, Dr. Fisher completed a five year general surgery residency at The Ohio State University under Dr. E. Christopher Ellison. He then culminated his surgical training at Vanderbilt University under Dr. Thomas C. Naslund.

Dr. Fisher is a board certified Vascular surgeon and is a member of The Surgical Clinic in Nashville, TN. He serves as the Co-Chairman of the Tristar Vascular Workgroup, Physician Lead for Vascular Services HCA Tristar Division, and co-Director of the Center for Functional Limb Preservation at Tristar Centennial Medical Center. As the physician lead of Vascular services at the division level, Dr. Fisher provides leadership and the vision of providing cutting-edge, personalized, high quality care for vascular disease; in a truly collaborative environment. Dr. Fisher specializes in complex open, endovascular and hybrid techniques in the treatment of aortic disease and lower extremity occlusive disease. He has a special interest in the treatment of advanced lower extremity disease in patients at higher risk for limb loss. Dr. Fisher has an additional focus on eliminating disparities cardiovascular disease outcomes that adversely affect the Black community.

Dr. Fisher owes his success to his wife and friend of 21 years, Latita Fisher. They have four wonderful children (Bryan Jr., Breahn, Breya, and Brylee).

Jeff Page, DPM

Foot and Ankle Surgeon

Dr. Page is a podiatric medical educator board certified in wound care and in foot and ankle surgery. Recently retired as the Founding Dean and Professor of podiatric medicine and surgery of the Arizona College of Podiatric Medicine at Midwestern University in Glendale, Arizona, Dr. Page also served as Dean and Professor at the California College of Podiatric Medicine in San Francisco, California. He twice served as the Chief of the Podiatry Section and Residency Director at the Carl T. Hayden VA Medical Center in Phoenix, Arizona. He is also a Visiting Professor at the Nankai University School of Medicine in Tianjin, China. Dr. Page has published over 75 manuscripts and peer-reviewed posters and served as a consultant on several medical advisory boards for biotechnology.

Dr. Page was awarded fellowships by the American College of Foot and Ankle Surgeons, the American Professional Wound Care Association, the American College of Foot and Ankle Orthopedics and Medicine, and the American Society of Podiatric Dermatology. He received the Kenison Award, the highest honor bestowed by the American Podiatric Medical Students Association and was selected several times as one of the most influential podiatrists in the U.S. by Podiatry Management magazine. He was also given the John R. Burdick Altruism Award by DOCare International.

Dr. Page has been deeply involved in service to the community and the profession. He is the founding Chairman of the Board for the FUEGO Foundation, dedicated to expanding aid and health care access to under-resourced populations abroad. For 18 years he helped to lead interdisciplinary missions to Guatemala and Mexico and the foundation supports foreign clinics and medical trainees desirous of serving health related missions. Dr. Page served for many years on the Board of Neighborhood Outreach Access to Health (NOAH) which operates ten community clinics for the under-served in greater Phoenix and he served for several years with the American Diabetes Association in Arizona. He has devoted many years to the provision of health care to the homeless through direct patient care and through the supervision of volunteer student organizations dedicated to support of the homeless.